TW202228739A - 結核菌萃取物之新穎用途 - Google Patents

結核菌萃取物之新穎用途 Download PDF

Info

Publication number
TW202228739A
TW202228739A TW110137520A TW110137520A TW202228739A TW 202228739 A TW202228739 A TW 202228739A TW 110137520 A TW110137520 A TW 110137520A TW 110137520 A TW110137520 A TW 110137520A TW 202228739 A TW202228739 A TW 202228739A
Authority
TW
Taiwan
Prior art keywords
cancer
cells
extract
tumor
immune adjuvant
Prior art date
Application number
TW110137520A
Other languages
English (en)
Chinese (zh)
Inventor
堀井孝幸
田中貴男
Original Assignee
日商志瑞亞新藥工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商志瑞亞新藥工業股份有限公司 filed Critical 日商志瑞亞新藥工業股份有限公司
Publication of TW202228739A publication Critical patent/TW202228739A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110137520A 2020-10-09 2021-10-08 結核菌萃取物之新穎用途 TW202228739A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020-171491 2020-10-09
JP2020171491 2020-10-09
JP2020217698 2020-12-25
JP2020-217698 2020-12-25

Publications (1)

Publication Number Publication Date
TW202228739A true TW202228739A (zh) 2022-08-01

Family

ID=81126102

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110137520A TW202228739A (zh) 2020-10-09 2021-10-08 結核菌萃取物之新穎用途

Country Status (12)

Country Link
US (1) US20230372476A1 (https=)
EP (1) EP4226939A4 (https=)
JP (1) JPWO2022075458A1 (https=)
KR (1) KR20230084177A (https=)
CN (1) CN116322771A (https=)
AU (1) AU2021357131A1 (https=)
BR (1) BR112023006220A2 (https=)
CA (1) CA3194869A1 (https=)
MX (1) MX2023004103A (https=)
TW (1) TW202228739A (https=)
WO (1) WO2022075458A1 (https=)
ZA (1) ZA202304219B (https=)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS568320A (en) * 1979-07-04 1981-01-28 Chisato Maruyama Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
JPS5632489A (en) * 1979-08-28 1981-04-01 Mitsui Toatsu Chem Inc Antitumor active substance and its pharmaceutical
JPH0680574A (ja) * 1991-11-05 1994-03-22 Kiichiro Ozaki 間接的癌治療剤
WO1998056941A1 (en) * 1995-12-12 1998-12-17 Tai Ho Chung Carbohydrate complex extracted from mycobacterium tuberculosis and process for the preparation thereof
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
GB0123756D0 (en) * 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
PT1618128E (pt) * 2003-04-23 2010-10-13 Max Planck Gesellschaft Vacina de tuberculose com eficácia melhorada
US20090208486A1 (en) * 2004-03-09 2009-08-20 Makoto Taketo Pharmaceutical composition comprising cxcr3 inhibitor
US20140199347A1 (en) * 2011-02-10 2014-07-17 University Of Louisville Research Foundation, Inc. Adjuvant compositions with 4-1bbl
JP5999639B2 (ja) * 2011-11-25 2016-09-28 国立研究開発法人産業技術総合研究所 免疫刺激因子担持微粒子
CN105999260B (zh) * 2016-05-13 2019-12-10 四川大学 氢氧化铝凝胶-氯化钠复合免疫佐剂及其制备方法和用途
JP7367906B2 (ja) 2019-04-10 2023-10-24 株式会社 シコク 手摺装置
EP4082577A4 (en) * 2019-12-27 2024-01-03 Zeria Pharmaceutical Co., Ltd. CANCER TREATMENT METHOD AND DRUG

Also Published As

Publication number Publication date
AU2021357131A1 (en) 2023-05-25
AU2021357131A9 (en) 2025-03-13
EP4226939A4 (en) 2024-11-13
CA3194869A1 (en) 2022-04-14
EP4226939A1 (en) 2023-08-16
CN116322771A (zh) 2023-06-23
KR20230084177A (ko) 2023-06-12
JPWO2022075458A1 (https=) 2022-04-14
BR112023006220A2 (pt) 2023-05-09
MX2023004103A (es) 2023-04-27
WO2022075458A1 (ja) 2022-04-14
US20230372476A1 (en) 2023-11-23
ZA202304219B (en) 2023-12-20

Similar Documents

Publication Publication Date Title
Corrales et al. Innate immune signaling and regulation in cancer immunotherapy
JP6858128B2 (ja) 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
JP2020183413A (ja) Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法
TWI855989B (zh) 藉由投予抗her3抗體－藥物複合體之egfr－tki抗性之非小細胞肺癌的治療方法
JP2024099527A (ja) 移植片対宿主病を処置し予防する方法
JP2020164539A (ja) 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法
JP2022527481A (ja) 生物活性が改変されたインターロイキン－２バリアント
TW201639866A (zh) 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
JP2023081935A (ja) がん免疫療法のための組成物および方法
JP7028765B2 (ja) ベンズアミドおよび活性化合物組成物および使用方法
JPWO2021182573A5 (https=)
CN111372584A (zh) Tim-3和pd-1途径的双重抑制剂
US20240262909A1 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
KR20220116438A (ko) 암 치료를 위한 미생물총 및 대사산물의 힘 활용
TW201716084A (zh) 組合物及其用途與治療
WO2018039332A1 (en) Immunoswitch nanoparticles for reprogrammed t cell responses
WO2020086440A1 (en) Immunomodulatory compounds
JP7080234B2 (ja) ベンズアミドおよび活性化合物組成物および使用方法
TW202228739A (zh) 結核菌萃取物之新穎用途
CN114980930A (zh) 癌症治疗方法及药物
EP4151224B1 (en) COMPOSITION TO IMPROVE THE IMMUNE RESPONSE THROUGH THE USE OF AN ACTIVATION FUNCTION OF DENDRITIC CELLS FROM STROMAL VASCULAR FRACTIONS ISOLATED FROM ADIPOSE TISSUES
EP4707296A1 (en) Interleukin-2 variants with modified biological activity
EP4707295A1 (en) Interleukin-2 variants with modified biological activity
US20260069705A1 (en) Methods and compositions for enhanced antigen presentation in the tumor microenvironment
KR102584306B1 (ko) 항종양제 및 항종양 효과 증강제